John H. Landon was appointed to the board of directors of Riot Pharmaceuticals in December 2008 and serves as chair of the Compensation Committee and member of the Nominating and Corporate Governance Committee. As of the 2014 proxy filing, he was 73 years old.
Landon spent more than 30 years with DuPont until his retirement in 1996, culminating as Vice President and General Manager of medical products from 1992 to 1996 with worldwide responsibility for DuPont's medical products businesses (approximately $1 billion in annual sales and 5,000+ employees). He previously served as Chairman of Cholestech Corporation prior to its 2007 sale to Inverness Medical and as a director of Digene Corporation prior to its 2007 sale to Qiagen.
Landon is currently a member of the board of LipoScience, Inc. (NASDAQ Global Select), an in vitro diagnostics company, and serves as a trustee of Christiana Care Health System and advisor to Water Street Healthcare Partners. He holds a B.S. in chemical engineering from the University of Arizona.
Biography extracted from Riot DEF 14A filed 2014-04-30 View cached copy (2026-09-27)Live source ↗
Roles
Contiguous filings for the same role are collapsed into a single tenure span. Click a row to see the underlying filings.
| Company | Role | Tenure | Filings |
|---|---|---|---|
| Riot | Director | 2008-12 → present (17y 11mo) | 9 |
Show 9 underlying filings | |||
Insider transactions
Totals for this person
| Bucket | Invested (shares) | Invested (USD) | Divested (shares) | Divested (USD) | Net direction | Txns | Invested @ last price | Divested @ last price |
|---|---|---|---|---|---|---|---|---|
| All time | 290,806 | $0 | - | $0 | Flat | 8 | $3.73M | $0 |
| 2015 | 53,000 | $0 | - | $0 | Flat | 1 | $678.9K | $0 |
| 2014 | 34,000 | $0 | - | $0 | Flat | 1 | $435.5K | $0 |
| 2013 | 26,000 | $0 | - | $0 | Flat | 1 | $333.1K | $0 |
| 2012-Q4 | 17,806 | $0 | - | $0 | Flat | 1 | $228.1K | $0 |
| 2013-Q1 | 26,000 | $0 | - | $0 | Flat | 1 | $333.1K | $0 |
| 2014-Q1 | 34,000 | $0 | - | $0 | Flat | 1 | $435.5K | $0 |
| 2015-Q1 | 53,000 | $0 | - | $0 | Flat | 1 | $678.9K | $0 |
Invested = shares acquired (buys, grants, option exercises) — insider adding to the position. Divested = shares reduced (sells, dispositions, tax-withholding) — cash flowing TO the insider. Net direction shows which side wins on dollar terms in each bucket. % of holder's stake not yet computed (pending Form 3/4 holdings ingest). See methodology. The two @ last price columns restate the same share counts at the most recent share price we read (close of 2026-10-30); they are a valuation, not a cash flow, and they move every day the market does.
All transactions
| Date | Company | Kind | Shares | Amount (USD) | Value @ last price |
|---|---|---|---|---|---|
| 2015-01-12 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 53,000 | - | $678.9K |
| 2014-01-06 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 34,000 | - | $435.5K |
| 2013-01-23 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 26,000 | - | $333.1K |
| 2012-12-11 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 17,806 | - | $228.1K |
| 2012-04-02 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 10,000 | - | $128.1K |
| 2011-01-05 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 50,000 | - | $640.5K |
| 2010-01-19 | Riot | Grant / award / vesting · Option - Right to Buy | 50,000 | - | $640.5K |
| 2009-01-27 | Riot | Grant / award / vesting · Stock Options | 50,000 | - | $640.5K |